Jiangsu Hengrui Pharmaceuticals (01276): As of the end of November, it has repurchased a total of 8.89 million A shares.

Jiangsu Hengrui Pharmaceuticals (01276) announced the progress of the repurchase of the company's A shares: In November 2025, the company repurchased 979,000 shares through the Shanghai Stock Exchange trading system by centralized bidding, representing 0.015% of the total share capital of the company. The highest price paid for the repurchase was RMB 63.28 per share, the lowest price was RMB 59.32 per share, and the total amount paid was RMB 59.7885 million (excluding transaction costs). As of November 30, 2025, the company has repurchased a total of 8.8987 million shares through the Shanghai Stock Exchange trading system by centralized bidding, representing 0.13% of the total share capital of the company. The highest price paid for the repurchase was RMB 70.00 per share, the lowest price was RMB 59.32 per share, and the total amount paid was RMB 5.95 billion (excluding transaction costs).